DAFNA Capital Management’s Keros Therapeutics KROS Stock Holding History

DAFNA Capital Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,716	Closed	-$1.28M	–	81
2025 Q3	$1.28M	Sell	80,716 -49,600	-38%	-$733K	0.32%	55
2025 Q2	$1.74M	Hold	130,316	–	–	0.48%	40
2025 Q1	$1.33M	Hold	130,316	–	–	0.38%	47
2024 Q4	$2.06M	Buy	130,316 +56,562	+77%	+$2.94M	0.52%	37
2024 Q3	$4.28M	Buy	73,754 +6,000	+9%	+$296K	1.01%	26
2024 Q2	$3.1M	Hold	67,754	–	–	0.74%	34
2024 Q1	$4.49M	Sell	67,754 -6,607	-9%	-$392K	1.02%	29
2023 Q4	$2.96M	Buy	74,361 +8,400	+13%	+$263K	0.71%	37
2023 Q3	$2.1M	Buy	65,961 +18,300	+38%	+$683K	0.65%	39
2023 Q2	$1.92M	Buy	47,661 +28,300	+146%	+$1.24M	0.52%	42
2023 Q1	$827K	Sell	19,361 -13,639	-41%	-$689K	0.25%	50
2022 Q4	$1.58M	Sell	33,000 -6,000	-15%	-$280K	0.45%	49
2022 Q3	$1.47M	Hold	39,000	–	–	0.39%	49
2022 Q2	$1.08M	Buy	+39,000	New	+$1.71M	0.29%	61

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

DAFNA Capital Management's KROS Position: Q4 2025 in Review

DAFNA Capital Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 80,716 shares — an estimated $1.28M sold.

DAFNA Capital Management first reported a position in KROS in Q2 2022 and held it in 14 quarters. The position peaked at $4.49M in Q1 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

DAFNA Capital Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
DAFNA Capital Management sold 80,716 Keros Therapeutics shares in Q4 2025, an estimated $1.28M.
DAFNA Capital Management first reported a position in Keros Therapeutics in Q2 2022 and held it in 14 quarters.
DAFNA Capital Management's Keros Therapeutics position peaked at $4.49M in Q1 2024.
166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.